BR112017003651A2 - derivados de isoquinolinona úteis no tratamento de câncer - Google Patents

derivados de isoquinolinona úteis no tratamento de câncer

Info

Publication number
BR112017003651A2
BR112017003651A2 BR112017003651A BR112017003651A BR112017003651A2 BR 112017003651 A2 BR112017003651 A2 BR 112017003651A2 BR 112017003651 A BR112017003651 A BR 112017003651A BR 112017003651 A BR112017003651 A BR 112017003651A BR 112017003651 A2 BR112017003651 A2 BR 112017003651A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
derivatives useful
isoquinolinone derivatives
compound
isoquinolinone
Prior art date
Application number
BR112017003651A
Other languages
English (en)
Inventor
Kruczynski Anna
Bachir Kaloun El
Schmitt Philippe
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112017003651A2 publication Critical patent/BR112017003651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a um composto da seguinte fórmula (i), ou um sal e/ou solvato farmaceuticamente aceitável do mesmo, particularmente para uso como um fármaco, particularmente no tratamento de câncer, bem como às composições farmacêuticas contendo tal composto e aos processos para preparar tal composto.
BR112017003651A 2014-09-02 2015-09-02 derivados de isoquinolinona úteis no tratamento de câncer BR112017003651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306352 2014-09-02
PCT/EP2015/070082 WO2016034642A1 (en) 2014-09-02 2015-09-02 Isoquinolinone derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017003651A2 true BR112017003651A2 (pt) 2017-12-05

Family

ID=51494243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003651A BR112017003651A2 (pt) 2014-09-02 2015-09-02 derivados de isoquinolinona úteis no tratamento de câncer

Country Status (8)

Country Link
US (1) US9944641B2 (pt)
EP (1) EP3189051A1 (pt)
JP (1) JP2017525734A (pt)
CN (1) CN106795154B (pt)
BR (1) BR112017003651A2 (pt)
MX (1) MX2017002544A (pt)
RU (1) RU2690853C2 (pt)
WO (1) WO2016034642A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481826B1 (en) * 2016-07-08 2021-11-03 Rigel Pharmaceuticals, Inc. Tyrosine kinase inhibitors
CN106699608A (zh) * 2016-12-26 2017-05-24 常州大学 一种含有强吸电子基团的苯胍及其盐的制备方法
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
AU2012209373A1 (en) 2011-01-24 2013-04-11 Glaxosmithkline Llc Isoquinoline compounds and methods for treating HIV
RU2014113236A (ru) * 2011-09-20 2015-10-27 Ф. Хоффманн-Ля Рош Аг Соединения имидазопиридина, композиции и способы применения
WO2013110585A1 (en) * 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
JP6553589B2 (ja) * 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法

Also Published As

Publication number Publication date
CN106795154B (zh) 2019-07-05
JP2017525734A (ja) 2017-09-07
RU2017108909A (ru) 2018-10-03
RU2690853C2 (ru) 2019-06-06
EP3189051A1 (en) 2017-07-12
MX2017002544A (es) 2017-07-19
US9944641B2 (en) 2018-04-17
WO2016034642A1 (en) 2016-03-10
US20170240544A1 (en) 2017-08-24
CN106795154A (zh) 2017-05-31
RU2017108909A3 (pt) 2018-12-13

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
EA201692003A1 (ru) Макроциклические производные пиримидина
PH12016501462A1 (en) Neprilysin inhibitors
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
TW201613864A (en) Novel compounds
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
PH12018501709A1 (en) Naphthridinedione derivatives
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak
BR112017003880A2 (pt) derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak
BR112018009482A2 (pt) composto, método para preparar um composto, e, composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.